Table 1.
Baseline characteristics of patients according to LIPI group.
| Immunotherapy-Treated Patients | Control Patients | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Whole Cohort * (N = 82) |
LIPI Good (N = 30) |
LIPI Intermediate (N = 26) |
LIPI Poor (N = 13) |
p | Whole Cohort (N = 126) |
LIPI Good (N = 73) |
LIPI Intermediate (N = 33) |
LIPI Poor (N = 13) |
p |
| Age > 65 | 18 (22%) | 6 (20%) | 8 (31%) | 1 (8%) | 0.26 | 28 (22%) | 17 (23%) | 7 (21%) | 1 (8%) | 0.54 |
| Unknown | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | ||
| Sex | 0.43 | 0.03 | ||||||||
| Female | 38 (46%) | 11 (37%) | 14 (54%) | 6 (46%) | 73 (58%) | 37 (51%) | 23 (70%) | 11 (85%) | ||
| Male | 44 (54%) | 19 (63%) | 12 (46%) | 7 (54%) | 53 (42%) | 36 (49%) | 10 (30%) | 2 (15%) | ||
|
FNCLCC grade median [IQR] |
2 [2;3] | 2 [1.75;3] | 3 [2;3] | 2 [2;3] | 0.10 | 2 [1;3] | 2 [1;3] | 2 [1;3] | 2 [2;3] | 0.11 |
| Unknown | 22 | 10 | 5 | 3 | 28 | 20 | 4 | 4 | ||
| Genomic profile | 0.08 | 0.01 | ||||||||
| Complex karyotype |
44 (54%) | 15 (50%) | 19 (73%) | 5 (38%) | 62 (49%) | 29 (40%) | 21 (64%) | 10 (77%) | ||
| Translocation- related sarcoma |
37 (46%) | 15 (50%) | 7 (27%) | 8 (62%) | 64 (51%) | 44 (60%) | 12 (36%) | 3 (23%) | ||
| Unknown | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Histology | 0.02 | 0.06 | ||||||||
| Angiosarcoma | 6 (7%) | 2 (7%) | 1 (4%) | 1 (8%) | 6 (5%) | 4 (5%) | 1 (3%) | 0 (0%) | ||
| Leiomyosarcoma | 22 (27%) | 6 (20%) | 13 (50%) | 2 (15%) | 32 (25%) | 15 (21%) | 12 (36%) | 5 (38%) | ||
| Myxoid liposarcoma | 5 (6%) | 1 (3%) | 1 (4%) | 2 (15%) | 6 (5%) | 4 (5%) | 2 (6%) | 0 (0%) | ||
| Synovial sarcoma | 7 (9%) | 1 (3%) | 2 (8%) | 4 (31%) | 5 (4%) | 3 (4%) | 0 (0%) | 2 (15%) | ||
| Undifferentiated pleomorphic sarcoma |
5 (6%) | 2 (7%) | 3 (12%) | 0 (0%) | 11 (9%) | 6 (8%) | 4 (12%) | 1 (8%) | ||
| Well/de-differentiated liposarcoma |
9 (11%) | 7 (23%) | 2 (8%) | 0 (0%) | 45 (36%) | 29 (40%) | 11 (33%) | 0 (0%) | ||
| Other | 28 (34%) | 11 (37%) | 4 (15%) | 4 (31%) | 21 (17%) | 12 (16%) | 3 (9%) | 5 (38%) | ||
| Stage at inclusion | 0.39 | 0.66 | ||||||||
| Locally advanced | 10 (12%) | 2 (7%) | 5 (19%) | 1 (8%) | 17 (13%) | 9 (12%) | 6 (18%) | 1 (8%) | ||
| Metastatic | 72 (88%) | 28 (93%) | 21 (81%) | 12 (92%) | 109 (87%) | 64 (88%) | 27 (82%) | 12 (92%) | ||
|
N prior systemic lines median [IQR] |
3 [2;4] | 4 [2;4] | 3 [2;4] | 4 [3;5] | 0.19 | 2 [1;3] | 2 [1;3] | 2 [1;3] | 2 [2;3] | 0.79 |
|
Prior
anthracycline |
74 (90%) | 27 (90%) | 22 (85%) | 13 (100%) | 0.44 | 94 (75%) | 55 (75%) | 25 (76%) | 11 (85%) | 0.898 |
|
Performance
status > 0 |
52 (63%) | 17 (57%) | 15 (58%) | 13 (100%) | 0.01 | 75 (60%) | 33 (45%) | 26 (79%) | 11 (84%) | 0.001 |
| dNLR > 3 | 31 (38%) | 0 (0%) | 14 (54%) | 13 (100%) | <0.001 | 27 (21%) | 0 (0%) | 14 (42%) | 13 (100%) | <0.001 |
| LDH > N | 25 (36%) | 0 (0%) | 12 (46%) | 13 (100%) | <0.001 | 32 (27%) | 0 (0%) | 19 (58%) | 13 (100%) | <0.001 |
| Unknown | 13 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | ||
| Albumin > 35 g/L | 67 (78%) | 26 (87%) | 22 (85%) | 7 (54%) | 0.05 | 81 (64%) | 48 (66%) | 23 (70%) | 7 (54%) | 0.59 |
* Whole cohort including patients with non-evaluable LIPI score. Abbreviations: dNLR, derived neutrophil-to-lymphocyte ratio; FNCLCC, Federation Nationale des Centres de Lutte Contre le Cancer grading system; IQR, Interquartile Range; LIPI, Lung immune prognostic index.